1569P - The use of biosimilar epoetins in the management of chemotherapy-induced anaemia (CIA) in patients with lung cancer: a subanalysis of the ORHEO study

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Supportive Care
Lung and other Thoracic Tumours
Presenter Mauricette Michallet
Authors M. Michallet1, E. Luporsi2, P. Soubeyran3, H. Albrand4
  • 1Centre Hospitalier Lyon Sud, 69495 - Lyon-Pierre Bénite/FR
  • 2Medical Oncology, Centre Alexis Vautrin, 54500 - Vandœuvre-lès-Nancy/FR
  • 3Department Of Medical Oncology, Institut Bergonié and Université Bordeaux Segalen, 33000 - Bordeaux/FR
  • 4Medical Director, Laboratoire HOSPIRA France, 92360 - Meudon La Forêt/FR

Abstract

An observational, longitudinal, multicentre study (ORHEO; place of biOsimilaRs in the therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology) is being conducted in France to assess the efficacy and safety of biosimilar epoetins for the treatment of CIA in the clinical setting. A total of 2310 patients with solid tumours, myeloma and lymphoma were included in the study. In the subanalysis, we assess the use of biosimilar epoetins in patients with lung cancer. A total of 421 patients >18 years with CIA (haemoglobin [Hb] <11g/dL) associated with lung cancer and eligible for treatment with biosimilar epoetin were included in this analysis. Patient characteristics were recorded at baseline along with anaemia-related information such as observed and target Hb (as chosen by the treating clinician), brand and dose of epoetin biosimilar prescribed, and details of any other parallel treatments. Patients were followed-up at 3 and 6 months. Analyses included achievement of target Hb and Hb response (defined as Hb reaching ≥10 g/dL, an increase in Hb levels of at least 1 g/dL since inclusion visit, or reaching target Hb set by doctor at start of study, without any blood transfusions in the 3 weeks prior to measurement). Adverse events were also recorded.

Of the patients included in this study, 33.5% had a stage III tumour and 30.8% a stage IV tumour, while metastases were identified in 71.5% of patients. At baseline, average Hb levels were 9.5 g/dL, with 36.8 % of patients classed as having moderate anaemia. All patients received epoetin zeta (Retacrit®, Hospira UK Ltd.) Response to treatment with biosimilar epoetin was achieved in 76.7% and 86.0% of patients after 3 and 6 months, respectively, while average Hb levels had increased by 1.4 g/dL and 1.7 g/dL at 3 and 6 months, respectively. At 6 months, the transfusion rate was 1.1%, the rate of clinically significant adverse events was 16.7%, while the rate of thrombotic events was 2.4%. In conclusion, biosimilar epoetin was effective and well tolerated in the treatment of CIA in patients with lung cancer.

Disclosure

M. Michallet: I have received honoraria from Hospira for advisory boards and consulting,

E. Luporsi: I have received honoraria from Hospira for advisory boards and consulting,

P. Soubeyran: I have received honoraria from Hospira for advisory boards and consulting,

H. Albrand: Employed by Hospira.